Test a hepatitis B–targeted treatment for serious liver failure
Part of Digestive system, Infections clinical trials.
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hepatitis B that is still active (recent positive test for hepatitis B surface antigen or hepatitis B DNA).
- You are between 18 and 65 years old.
- You have serious liver failure with blood test results showing very high bilirubin and abnormal blood clotting.
- Your platelet count is above 50,000 (50×10^9/L).
- You do not have other active liver diseases, liver cancer, or another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
This trial tests a new drug called AS1501 for people with acute-on-chronic liver failure (a sudden worsening of chronic liver disease). It aims to see if the drug can help improve liver function and reduce the need for a liver transplant. You may be eligible if you are in the early or middle stage of this condition and have a specific blood marker (high TRAIL level).
This trial looks at how well stem cell (MSC) treatment works for people with severe liver failure caused by hepatitis B. It checks what factors affect the success of the treatment.
This trial studies a treatment called the Double Plasma Molecular Adsorption System (DPMAS) for people with acute-on-chronic liver failure while they are in the ICU. It aims to see whether filtering certain substances from blood can improve outcomes and safety for critically ill patients.
This trial tests if infusions of stem cells from donated umbilical cords can help people with a severe type of liver failure caused by hepatitis B. It aims to see if the treatment is safe and can improve liver function.
This Phase 2 trial tests an injection medicine (F573) to see if it can improve people with liver injury, drug-related liver damage, or liver failure. You may be screened with blood tests, liver stiffness measurements, and possibly symptom checks.
Hear when a new Acute-On-Chronic Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.